The effect of spironolacton on airway resistance with impulse oscillometry in patients with congestive heart failure

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104196231N1

Enrollment

Registered

2011-09-08

Start date

2011-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure (CHF). chronic cardiopulmonary disease

Interventions

spironolactone 25mg daily for 1 month.

Treatment - Drugs

spironolactone 25mg daily for 1 month

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Ejection Fraction <40; Taking Beta blocker, ACE inh, Diuretics and Asperin; they should not use spironolactone. Exclusion criteria: Respiratory disease; CXR Pathology during recent 1 year; Smoking from 6 month ago; FEV1 <75; Neurological problem.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Airway resistance. Timepoint: 1 month. Method of measurement: impulse oscillometry.	—

Secondary

Measure	Time frame
Central and peripheral pulmonary resistance such as r5.r20,x5,x20. Timepoint: 1 month. Method of measurement: impulsed osilometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mmohammad Hasan Adel

Ahvaz university of medical sciences

adel-smh@ajums.ac.ir+98 916 111 0506

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026